GRCE Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Grace Therapeutics's net margin of -49.65%. Grace Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 499.01%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that Grace Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Grace Therapeutics is more attractive than NovaBay Pharmaceuticals.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Grace Therapeutics's net income of -$4.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Grace Therapeutics's net margin of -2357.27%. Grace Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 499.01%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Grace Therapeutics, analysts believe Palatin Technologies is more attractive than Grace Therapeutics.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Grace Therapeutics's net income of -$4.2M is lower than Palatin Technologies's net income of -$2.4M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Grace Therapeutics's net margin of -18.58%. Grace Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 499.01%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Grace Therapeutics has higher upside potential than Retractable Technologies, analysts believe Grace Therapeutics is more attractive than Retractable Technologies.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Grace Therapeutics's net income of -$4.2M is lower than Retractable Technologies's net income of -$1.9M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -- compared to Grace Therapeutics's net margin of -125.59%. Grace Therapeutics's return on equity of -- beat SpringWorks Therapeutics's return on equity of -46.69%.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 499.01%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 99.82%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than SpringWorks Therapeutics quarterly revenues of $61.5M. Grace Therapeutics's net income of -$4.2M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 14.11x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.